23:04 , May 8, 2019 |  BC Extra  |  Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

Moderna debuts candidate for rare glycogen storage disease  Moderna Inc. (NASDAQ:MRNA) revealed a new preclinical mRNA candidate to treat glycogen storage disease type Ia -- mRNA-3745, which encodes G6PC. The company presented data at the...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
18:43 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat mucopolysaccharidosis II (MPS II, Hunter syndrome) and SB-318 to...
00:54 , Feb 8, 2019 |  BC Extra  |  Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) lost $3.71 (31%) to $8.31 Thursday after the company reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat...
17:46 , Jan 11, 2019 |  BC Week In Review  |  Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
20:42 , Jan 8, 2019 |  BC Extra  |  Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
19:14 , Nov 16, 2018 |  BC Week In Review  |  Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round Nov. 15 to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and...
00:13 , Nov 16, 2018 |  BC Extra  |  Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and Gimv led...
22:38 , Oct 8, 2018 |  BC Extra  |  Preclinical News

Tokyo team IDs monocyte subtype for inflammation recovery, repair

Tokyo University of Pharmacy and Life Sciences researchers identified a subpopulation of immunoregulatory monocytes that can resolve systemic inflammation and promote tissue repair, suggesting the monocyte subset could be targeted to treat inflammatory diseases such...
18:37 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Target enzyme undetected at week 16 in Sangamo's MPS II gene editing trial

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported data showing that plasma iduronate 2-sulfatase (IDS) activity was below the level of quantification through 16 weeks in the Phase I/II CHAMPIONS trial evaluating SB-913 to treat mucopolysaccharidosis II (MPS...